Blinding : the process of preventing one or more of patients, clinicians, investigators, and data analysts from knowing whether individual patients are receiving the investigational intervention(s) or the control (or standard) intervention(s) in a clinical trial. (Also known as masking.) Blinding is intended to eliminate the possibility that knowledge of which intervention is being received will affect patient outcomes, investigator behaviors that may affect outcomes, or assessment of outcomes. Blinding is not always practical (. when comparing surgery to drug treatment), but it should be used whenever it is possible and compatible with optimal patient care. The terms “single-blinded,” “double-blinded,” and “triple-blinded” refer to which parties are blinded, ., one or more of patients, investigators, and data analysts; however, these terms are used inconsistently and the specific parties who are blinded in a trial should be identified.
Different testosterone esters are often blended into one injectable preparation. In some cases up to seven esters are used, but the most popular formulation is that of Sustanon 250 where four esters are mixed together. This is done to take advantage of the faster acting esters while still only requiring weekly or bi-weekly injections. It is often believed to be a superior form of testosterone, but in reality it’s nothing more than just testosterone. One drawback of testosterone blends are that they incorporate esters with long carbon chains and those chains occupy allot of molecular weight, so the actual dosage of hormone is less than one would obtain from shorter esters like propionate. Testosterone blends are most useful during bulking phases where frequent injections are not possible.